CPA
SRPT icon

Cowen Prime Advisors’s Sarepta Therapeutics SRPT Stock Holding History

Cowen Prime Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-4,000
Closed -$246K – 224
2016
Q3 		$246K Buy
+4,000
New +$121K 0.11% 102
2016
Q2 		– Sell
-2,500
Closed -$49K – 242
2016
Q1 		$49K Buy
+2,500
New +$43.7K 0.02% 146

Other funds holding SRPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CC
Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
TCP
Tourbillon Capital Partners New York $6.26M AUM 42.29% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Cowen Prime Advisors's SRPT Position: Q4 2016 in Review

Cowen Prime Advisors sold out of Sarepta Therapeutics (SRPT) in Q4 2016, closing a stake of 4,000 shares — an estimated $246K sold.

Cowen Prime Advisors first reported a position in SRPT in Q1 2016 and held it in 2 quarters. The position peaked at $246K in Q3 2016. 177 funds tracked by Wall St. Rank hold SRPT as of Q4 2016.

  • Cowen Prime Advisors reported no remaining Sarepta Therapeutics position as of Q4 2016 after selling out during the quarter.
  • Cowen Prime Advisors sold 4,000 Sarepta Therapeutics shares in Q4 2016, an estimated $246K.
  • Cowen Prime Advisors first reported a position in Sarepta Therapeutics in Q1 2016 and held it in 2 quarters.
  • Cowen Prime Advisors's Sarepta Therapeutics position peaked at $246K in Q3 2016.
  • 177 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2016.

Based on Cowen Prime Advisors's 13F filing for Q4 2016, filed 9 Feb 2017.